SCHEMBL19902345

SCHEMBL19902345

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cnc2ccccn12

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.53
ROCK2 O75116 2/20 0.52
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
EPHB3 P54753 1/20 0.41
TGFBR1 P36897 2/20 0.41
KIT P10721 4/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ADORA2A P29274 1/20 0.39
RIPK2 O43353 4/20 0.39
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902368 0.90 ROCK1 (0.49) ROCK1ROCK2CCNA2CDK2TGFBR1
SCHEMBL19902518 0.88 CSF1R (0.46) ROCK1ROCK2CCNA2CDK2TGFBR1
SCHEMBL17452835 0.88 ROCK2 (0.58) ROCK1ROCK2CCNA2CDK2EPHB3
SCHEMBL19902392 0.87 ROCK1 (0.43) ROCK1ROCK2CCNA2CDK2TGFBR1
SCHEMBL19902519 0.87 TGFBR1 (0.46) ROCK1ROCK2CCNA2CDK2EPHB3
SCHEMBL19902525 0.87 ROCK1 (0.46) ROCK1ROCK2CCNA2CDK2TGFBR1
SCHEMBL19902591 0.86 CSF1R (0.46) ROCK1ROCK2CCNA2CDK2RIPK2
SCHEMBL19902478 0.86 PRMT5 (0.43) ROCK1ROCK2CCNA2CDK2TGFBR1
SCHEMBL19902615 0.86 CSF1R (0.49) ROCK1ROCK2CCNA2CDK2TGFBR1
SCHEMBL19902497 0.86 ROCK1 (0.42) ROCK1ROCK2CCNA2CDK2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK1 1/4885ROCK2 3/4885CCNA2 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.